Evidence map›Paper›PMID 41994182›Full record

ArticleIJTLD open2026

A mixed-method study to inform the development of long-acting injectable TB treatments.

A J F Bayot, M T Gler, E E Tolley, L Lorenzetti, E Namey, N Dinh, A Martinez, C Audibert, S Foraida, J Osborn and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in IJTLD open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

A J F BayotTB HIV Innovations and Clinical Research Foundation, Silang, Philippines.
M T GlerTB HIV Innovations and Clinical Research Foundation, Silang, Philippines.
E E TolleyFHI 360, Global Health and Population Research, Durham, NC, USA.
L LorenzettiFHI 360, Global Health and Population Research, Durham, NC, USA.
E NameyFHI 360, Global Health and Population Research, Durham, NC, USA.
N DinhFHI 360, Global Health and Population Research, Durham, NC, USA.
A MartinezFHI 360, Global Health and Population Research, Durham, NC, USA.
C AudibertMMV Medicines for Malaria Venture, Geneva, Switzerland.
S ForaidaTB Alliance Research and Development, New York City, NY, USA.
J OsbornGates Medical Research Institute, Cambridge, MA, USA.
D HoltzmanGates Medical Research Institute, Cambridge, MA, USA.
C VinnardGates Medical Research Institute, Cambridge, MA, USA.
E A TalbotGeisel School of Medicine at Dartmouth, Hanover, NH, USA.
C WellsGates Medical Research Institute, Cambridge, MA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDevelopment of long-acting injectable (LAI) formulations of TB drugs could transform global TB management. We assessed three hypothetical LAI treatment scenarios and seven product-specific characteristics among TB patients and survivors, TB clinicians, and other key stakeholders.

methodsA two-stage, mixed-method study was conducted in the Philippines. Stage 1 included semi-structured interviews with 15 key informants (KIs) from public health organisations, government, and clinical practices. Stage 2 entailed face-to-face surveys and a discrete choice experiment (DCE) with TB health providers (n = 51), adult TB patients on treatment (n = 247), and TB survivors (n = 54) in one urban and one semi-urban setting.

resultsCommon themes identified through KI interviews included goals of minimising treatment burden, maximising adherence and efficacy, primary care setting preference, and the ability to monitor response. Relative to the oral standard of care, most participants reported that the LAI TB treatment scenarios were acceptable. Body placement of the injection was a driving characteristic of treatment choice for patients; preference for LAI treatment delivered through a primary care setting was reported as positively influencing treatment choice across respondent types.

conclusionMulti-setting stakeholder input should guide development of LAI TB treatment so that developers can aim for acceptable product characteristics.

Indexed as

target regimen profilesthe Philippinestreatment adherencetuberculosis

Identifiers

PMID41994182
PMCPMC13080306

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.